SCHEMBL8515524

SCHEMBL8515524

CC(=O)OC[C@H]1OC(OC(=N)C(Cl)(Cl)Cl)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.59
THRB P10828 1/20 0.59
HSD17B10 Q99714 1/20 0.59
NR3C1 P04150 1/20 0.51
FYN P06241 1/20 0.51
ADRA2A P08913 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
ADRA2B P18089 1/20 0.51
DRD4 P21917 1/20 0.51
DRD3 P35462 1/20 0.51
CA2 P00918 7/20 0.51
TSHR P16473 1/20 0.48
CA12 O43570 6/20 0.47
CA1 P00915 5/20 0.47
CA9 Q16790 4/20 0.47
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
CA4 P22748 2/20 0.45
CA5A P35218 2/20 0.45
CA7 P43166 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15747016 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL1726948 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL17724779 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL20033571 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL17192718 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL1687338 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL18105805 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL15040789 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL414930 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL19304535 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662322-A1 SQUARAMIDE-MODIFIED ADENO-ASSOCIATED VIRUS VECTORS Coave Therapeutics (FR) 2025-12-17 EP disclosed
WO-2024165721-A1 SQUARAMIDE-MODIFIED ADENO-ASSOCIATED VIRUS VECTORS COAVE THERAPEUTICS (FR) 2024-08-15 WO disclosed
US-20140148400-A1 CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY METASIGNAL THERAPEUTICS INC. (CA) 2014-05-29 US disclosed
WO-2012070024-A1 CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY METASIGNAL THERAPEUTICS INC. (CA) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148400-A1 CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY CA7, CA4, CA2 CYP2D6 2204/4885THRB 4704/4885HSD17B10 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.